| Gene symbol | CNGA1 | Synonyms | CNCG, CNCG1, CNG-1, CNG1, RCNC1, RCNCa, RCNCalpha, RP49 | Type of gene | protein-coding |
| Chromosome | 4 | Map location | 4p12 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | cyclic nucleotide gated channel subunit alpha 1 | ||||
| GTO ID | GTC3784 |
| Trial ID | NCT06291935 |
| Disease | Retinitis Pigmentosa |
| Altered gene | CNGA1 |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | Gene transfer |
| Treatment | VG901 |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | A Prospective, Open-label, Phase 1b, Single-arm, Safety Study of an Intravitreal Application of a Recombinant Adeno-associated Virus Vector Expressing CNGA1 (AAV2.NN-CNGA1) in Patients With Retinitis Pigmentosa Due to CNGA1 Mutations |
| Year | 2024 |
| Country | Germany |
| Company sponsor | ViGeneron GmbH |
| Other ID(s) | VG901-2021 A|EU CT: 2023-504383-42-00 |
| Vector information | |||||||||
|
|||||||||
| Cohort 1 | |||||||
|
|||||||